[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563295":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":74,"centralContacts":78,"locations":84,"responsibleParty":103,"collaborators":53,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":53,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":114,"maxAge":53,"enrollmentInfo":115,"targetDuration":53,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":87,"whyStopped":53,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,16,20,24,28,32,36,42],{"label":9,"type":10,"description":11,"interventionNames":12},"Acute exposure: Placebo, Progressive Carbon Dioxide, Intermittent Hypoxia","EXPERIMENTAL","Study group will receive the three interventions in this order: Placebo, Progressive Carbon Dioxide, then Intermittent Hypoxia",[13,14,15],"Other: Acute Placebo Visit","Other: Acute Progressive Carbon Dioxide","Other: Acute Intermittent Hypoxia",{"label":17,"type":10,"description":18,"interventionNames":19},"Acute exposure: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide","Study group will receive the three interventions in this order: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Acute exposure: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide","Study group will receive the three interventions in this order: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Acute exposure: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo","Study group will receive the three interventions in this order: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo",[13,14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"Acute exposure: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia","Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia",[13,14,15],{"label":33,"type":10,"description":34,"interventionNames":35},"Acute exposure: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo","Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo",[13,14,15],{"label":37,"type":38,"description":39,"interventionNames":40},"Placebo Group","PLACEBO_COMPARATOR","Study group will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days intervention period. Subjects will then return within 7 days of their final training visit to repeat baseline testing",[41],"Other: Training: Placebo Control",{"label":43,"type":10,"description":44,"interventionNames":45},"Training Group","Training Study group will be complete 6 cycles of either progressive CO2 ramp protocol or the intermittent hypoxia protocol for 60 minutes for every visit during the 14 days. Subjects will then return within 7 days of their final training visit to repeat baseline testing",[46,47],"Other: Training: Progressive Carbon Dioxide Ramping","Other: Training: Intermittent Hypoxic Exposure",[49,54,58,62,66,70],{"type":6,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"Acute Placebo Visit","The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.",[21,25,17,9,33,29],null,{"type":6,"name":55,"description":56,"armGroupLabels":57,"otherNames":53},"Acute Progressive Carbon Dioxide","The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.",[21,25,17,9,33,29],{"type":6,"name":59,"description":60,"armGroupLabels":61,"otherNames":53},"Acute Intermittent Hypoxia","The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.",[21,25,17,9,33,29],{"type":6,"name":63,"description":64,"armGroupLabels":65,"otherNames":53},"Training: Progressive Carbon Dioxide Ramping","Intervention will consist of 6 to 10 study visits (3-5 sessions\u002Fweek) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.",[43],{"type":6,"name":67,"description":68,"armGroupLabels":69,"otherNames":53},"Training: Intermittent Hypoxic Exposure","Intervention will consist of 6 to 10 study visits (3-5 sessions\u002Fweek) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.",[43],{"type":6,"name":71,"description":72,"armGroupLabels":73,"otherNames":53},"Training: Placebo Control","Intervention will consist of 6 to 10 study visits (3-5 sessions\u002Fweek) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.",[37],[75],{"name":76,"affiliation":5,"role":77},"Courtney Wheatley-Guy","PRINCIPAL_INVESTIGATOR",[79],{"name":80,"role":81,"phone":82,"phoneExt":53,"email":83},"Jordan Parks","CONTACT","480-301-6616","parks.jordan@mayo.edu",[85],{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Mayo Clinic in Arizona","RECRUITING","Scottsdale","Arizona","85259","United States","US",{"type":94,"coordinates":95},"Point",[96,97],-111.89903,33.50921,{"lat":97,"lon":96},[100,101],{"name":80,"role":81,"phone":82,"phoneExt":53,"email":83},{"name":102,"role":77,"phone":53,"phoneExt":53,"email":53},"Courtney M Wheatley-Guy, PhD",{"type":77,"investigatorFullName":104,"investigatorTitle":105,"investigatorAffiliation":5,"oldNameTitle":53,"oldOrganization":53},"Courtney M. Wheatley","Principal Investigator","100563295","non-invasive-treatment-for-long-covid-post-covid-19-condition-brain-fog-100563295",false,"NCT06614309","Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog","Pilot Study to Investigate Possible Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog","Inclusion criteria:\n\n* English speaking\n* Diagnosis of Long COVID\n\nExclusion criteria:\n\n* Any history of:\n\n  * Coronary artery dissection or aortic dissection\n  * Neurological disease (e.g. dementia, Alzheimer's disease, or other brain-related disease)\n  * Cerebrovascular disease or stroke\n  * Aneurysm\n* If currently has:\n\n  * Moderate-severe chronic obstructive pulmonary disease\n  * Uncontrolled moderate-severe asthma\n  * Moderate-severe bronchiectasis\n  * Moderate-severe interstitial lung disease, requiring the use of supplemental oxygen\n  * A necessity to use supplemental oxygen, for any reason\n  * New or worsening symptoms (decompensation) of heart failure\n  * Right heart disease due to chronic pulmonary disease\u002Fsleep apnea\n  * Uncontrolled myocardial ischemia or angina\n  * Uncontrolled heart arrhythmias\n  * Heart or lung infection (e.g. myocarditis or pericarditis)\n  * Left main coronary artery stenosis\n  * Moderate-severe aortic stenosis\n  * Pulmonary embolism, pulmonary infarction, or other blood clots\n  * Severe respiratory disease\n  * Chronic kidney disease\n  * Chronic liver disease\n* Females of childbearing potential will complete a urine pregnancy test at their baseline visit to rule out pregnancy\n* BMI \\>40\n* Study staff unable to obtain adequate signal for cerebral blood flow","ALL","18 Years",{"count":116,"type":117},45,"ESTIMATED","INTERVENTIONAL",[120],"NA","This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.",[123],"Long COVID",[125,126,127,128],"brain fog","brain blood flow","heart rate variability","fatigue","2026-06-03",{"date":131,"type":132},"2026-06-05","ACTUAL",{"date":134,"type":132},"2024-09-24",{"date":136,"type":117},"2026-12",{"name":5,"class":6},1]